Regencell Bioscience Holdings Stock Pattern Recognition Identical Three Crows

RGC Stock  USD 23.23  -0.77  -3.21%   
This pattern recognition tool runs Identical Three Crows recognition and companion studies for Regencell Bioscience. The analysis highlights pattern recognition signals tied to momentum and continuation and frames technical signals with volatility and risk context.

Recognition
The function did not generate any output. Please change time horizon or modify your input parameters. This analysis covers forty-nine data points across the selected time horizon. The function did not return any valid pattern recognition events for the selected time horizon. The Identical Three Crows pattern describes Regencell Bioscience trend with bearish reversal signal.

Regencell Bioscience Technical Analysis Modules

Most technical analysis of Regencell Bioscience help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Regencell from various momentum indicators to cycle indicators. When you analyze Regencell charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Stock Overview, Methodology & Data Sources

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine bioscience company. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Regencell Bioscience operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. The profile for Regencell Bioscience integrates fundamentals, price behavior, and sector exposure. Price behavior may show elevated responsiveness to broader market cycles. Regencell Bioscience has a market cap of 11.49 B, P/E of 26.21, ROE of -54.81%.

Methodology

Unless otherwise specified, financial data for Regencell Bioscience Holdings is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Regencell (USA Stocks:RGC) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Regencell Bioscience Holdings has active sell-side coverage. Source-validated coverage currently shows 15 approved analysts, while broader market-consensus totals may differ across providers due to methodology and update timing. 7 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board
Last reviewed on March 12th, 2026

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regencell Bioscience in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regencell Bioscience's short interest history, or implied volatility extrapolated from Regencell Bioscience options trading.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Cash Cows Idea
Cash Cows
Invested few shares
Macroaxis Index Idea
Macroaxis Index
Invested over 60 shares
Dividend Beast Idea
Dividend Beast
Invested over 40 shares
Blockchain Idea
Blockchain
Invested few shares
Warren Buffett Holdings Idea
Warren Buffett Holdings
Invested over 20 shares
Hedge Favorites Idea
Hedge Favorites
Invested few shares
Momentum Idea
Momentum
Invested few shares
Artificial Intelligence Idea
Artificial Intelligence
Invested few shares

More Resources for Regencell Stock Analysis

A comprehensive view of Regencell Bioscience starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Regencell Bioscience Holdings Stock. Outlined below are key reports that provide context for Regencell Bioscience Holdings Stock:
Regencell Bioscience has a market cap of 11.49 B, ROE of -54.81%. See Your Equity Center for portfolio-level analysis. This includes a position in Regencell Bioscience Holdings within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
With Regencell Bioscience showing P/E 26.21 and ROE -54.81%, investors get more value when this analysis is combined with the diversification and construction tools below. The return profile should be cross-checked with the leverage and profitability tools to confirm it is equity-driven rather than debt-amplified. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
 Earnings Share
-0.01
 Return On Assets
-0.33
 Return On Equity
-0.55
Regencell Bioscience's market price can diverge from book value, the accounting figure shown on Regencell's balance sheet. Regencell Bioscience's market capitalization is 11.49 B. With a P/B ratio of 2363.44, the market values Regencell Bioscience well above its book equity. Enterprise value stands at 11.48 B. Value and price for Regencell Bioscience are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
Note that Regencell Bioscience's intrinsic value and market price are different measures derived from different inputs. For Regencell Bioscience, key inputs include a P/E ratio of 26.21, a P/B ratio of 2363.44, and ROE of -54.81%. The actual Regencell Bioscience transaction price is determined by real-time order flow on the exchange.